lapatinib has been researched along with er-086526 in 3 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (er-086526) | Trials (er-086526) | Recent Studies (post-2010) (er-086526) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 567 | 113 | 517 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dean-Colomb, W; Esteva, FJ | 1 |
| Casanova, C; Dazzi, C; Mazza, V; Verlicchi, A | 1 |
| Barinoff, J; Bauerschlag, DO; Bischoff, J; Costa, SD; Gerber, B; Grischke, EM; Herr, D; Krabisch, P; Kümmel, S; Loibl, S; Lübbe, K; Maass, N; Marmé, F; Müller, V; Mundhenke, C; Nekljudova, V; Schmidt, M; Schumacher, C; Seiler, S; Thill, M; von Minckwitz, G | 1 |
1 review(s) available for lapatinib and er-086526
| Article | Year |
|---|---|
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
1 trial(s) available for lapatinib and er-086526
| Article | Year |
|---|---|
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Furans; Humans; Ketones; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab | 2019 |
1 other study(ies) available for lapatinib and er-086526
| Article | Year |
|---|---|
Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Fatal Outcome; Female; Furans; Humans; Ketones; Lapatinib; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retreatment; Trastuzumab | 2015 |